Remsima broadens access

Hikma says it has considerably broadened access to infliximab in Morocco by introducing its Remsima biosimilar early last year. The Jordanian firm claims to have helped increase the size of the local market by about 50% to 11,000 vials per year whilst raising Remsima’s market share to more than 75%. “This example demonstrates how we grow our business and we are not limited to taking market share from the originator,” commented Hikma’s chief executive officer Siggi Olafsson.